Bayer's Litigation Costs in Focus -- Earnings Preview

Dow Jones
2025/11/11
 

By Billy Gray

 

Bayer is scheduled to report results for the third quarter on Wednesday. Here is what you need to know.

 

SALES FORECAST: The German pharmaceutical and agricultural group is expected to post third-quarter sales of 9.69 billion euros ($11.20 billion,) according to median consensus estimates provided by Vara Research. Bayer reported sales of 9.97 billion euros for the same period last year.

 

PROFIT FORECAST: Bayer is expected to post a third-quarter net loss of 413 million euros, narrowing from a net loss of 4.18 billion euros in the same period last year, when the company booked impairment losses at its crop-science business. The group is forecast to post earnings before interest, taxes, depreciation and amortization before special items--a key company metric--of 1.27 billion euros. For the third quarter of last year, Bayer made Ebitda before special items of 1.25 billion euros.

 

Shares in Bayer rose 11% during the third quarter and were up 37% since the start of the year through Monday's close.

 

WHAT TO WATCH

 

--U.S. LITIGATION: Bayer, since its 2018 acquisition of Monsanto, has been embroiled in litigation in the U.S. that has included accusations by thousands of former users that its Roundup weedkiller causes cancer, and that as of May had cost the company about $10 billion in legal payouts. "The outcome of pending appeals and the Erickson case before the Washington State Supreme Court will remain key watchpoints," analysts at U.S. bank Jefferies said. Bayer in August pledged to significantly contain litigation risk by the end of 2026.

--CURRENCY AND CROP HEADWINDS: Bayer said earlier this year that it expected significant currency fluctuations to weigh on sales and profits, in addition to cyclical agricultural weakness. "We expect [the third quarter] to be the softest quarter of the year due to the usual crop seasonality," Morgan Stanley analysts said.

 

Write to Billy Gray at william.gray@wsj.com

 

(END) Dow Jones Newswires

November 11, 2025 07:06 ET (12:06 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10